Industry news that matters to you.  Learn more

Stromedix Expands its Fibrosis Pipeline Through In-Licensing Agreement with UCSF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin alpha-v-beta-5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco (UCSF). Preclinical research suggests that alpha-v-beta-5 plays an important role in a variety of acute and chronic organ failure settings.

Sophic to Use $750K NCI Grant to Complete Cancer Biomarker Knowledgebase

Sophic Systems Alliance has snagged a two-year, Phase II $750,000 Small Business Innovation Research Grant from the National Cancer Institute that will fund the continued development of SCan-MarK — a knowledgebase that the company is intending as a one-stop shop for cancer biomarker information for oncologists, drug developers, and cancer researchers.

Compendia Bioscience Morphs Into Big Pharma’s Cancer Genomics Partner

Compendia Bioscience has evolved significantly since it spun out of the University of Michigan with its cancer genomics research software four years ago. Instead of just selling software and moving on to the next customer, Compendia co-founder and CEO, Daniel Rhodes, says that his firm has prospered by forming close ties to pharmaceutical companies that rely on the firm’s expertise and technology.

“We’re transforming from a software company only to really a collaboration partner with pharma, where we are licensing them access to our technology but also providing expertise and services,” Rhodes says. “So it’s a really exciting time for our company right now.”

Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome

Agilent Technologies Inc. today announced that its collaboration with the Institute for Systems Biology (ISB) and the Swiss Federal Institute of Technology (ETH Zurich) for the mapping of the complete human proteome by mass spectrometry is entering its second phase.

Mount Sinai Researchers Develop New Computational Method to Aide Analysis of Gene Expression Experiments

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers. Researchers can find the tool online at http://amp.pharm.mssm.edu/lib/chea.jsp. The data are published in Bioinformatics.